Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases

SH Li, CY Liu, PC Hsu, YF Fang, CC Wang… - Expert Review of …, 2018 - Taylor & Francis
Background: Brain metastases are observable in 20–40% of non-small cell lung cancer
patients, but standard treatments for such metastases may be intolerable to some. Epidermal …

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.

SH Li, CY Liu, PC Hsu, YF Fang, CC Wang… - Expert Review of …, 2017 - europepmc.org
Background Brain metastases are observable in 20-40% of non-small cell lung cancer
patients, but standard treatments for such metastases may be intolerable to some. Epidermal …

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases

SH Li, CY Liu, PC Hsu, YF Fang… - Expert review of …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Brain metastases are observable in 20-40% of non-small cell lung cancer
patients, but standard treatments for such metastases may be intolerable to some. Epidermal …

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases

SH Li, CY Liu, PC Hsu, YF Fang… - Expert Review of …, 2018 - pure.lib.cgu.edu.tw
Background: Brain metastases are observable in 20–40% of non-small cell lung cancer
patients, but standard treatments for such metastases may be intolerable to some. Epidermal …

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases

SH Li, CY Liu, PC Hsu, YF Fang… - Expert Review of …, 2018 - pure.lib.cgu.edu.tw
Background: Brain metastases are observable in 20–40% of non-small cell lung cancer
patients, but standard treatments for such metastases may be intolerable to some. Epidermal …